Inventor · disambiguated record
Matthew Pollard
Also filed as: POLLARD MATTHEW
22 granted patents·9 pending applications·103 citations·filing 2006–2025
94Inventor score
Files withTEVA PHARMACEUTICALS AUSTRALIA PTY LTD15CEPHALON LLC7CEPHALON INC4ATC IP LLC1CLARKE ADAM W1
Top patents by PatentIndex Score
31 records- 0195US10138296B2Antibodies that specifically bind to TL1ACEPHALON INC·Filed 2016·Granted Nov 27, 2018·17 cites·34 claims
- 0293US11220549B2Antibodies that specifically bind to TL1A and methods of treating respiratory tract diseasesCEPHALON INC·Filed 2018·Granted Jan 11, 2022·8 cites·31 claims
- 0390US10822422B2Antibodies against TL1a and uses thereofTEVA PHARMACEUTICALS AUSTRALIA PTY LTD·Filed 2016·Granted Nov 3, 2020·10 cites·13 claims
- 0489US11725052B2Anti-PAR-2 antibodies and methods of use thereofCEPHALON LLC·Filed 2021·Granted Aug 15, 2023·2 cites·26 claims
- 0589US7560688B2Mass analysis of mobility selected ion populationsUNIV WASHINGTON STATE·Filed 2006·Granted Jul 14, 2009·30 cites·66 claims
- 0687US9963515B2Anti-CD38 antibodies and fusions to attenuated interferon alpha-2BTEVA PHARMACEUTICALS AUSTRALIA PTY LTD·Filed 2015·Granted May 8, 2018·5 cites·27 claims
- 0787US9611322B2Fusions of antibodies to CD38 and attenuated interferon alphaTEVA PHARMACEUTICALS AUSTRALIA PTY LTD·Filed 2014·Granted Apr 4, 2017·6 cites·18 claims
- 0887US2025353919A1Antibodies Against TL1A and Uses ThereofTEVA PHARMACEUTICALS AUSTRALIA PTY LTD·Filed 2025·Application pending·0 cites
- 0986US10544199B2Interferon alpha 2B variantsTEVA PHARMACEUTICALS AUSTRALIA PTY LTD·Filed 2015·Granted Jan 28, 2020·7 cites·20 claims
- 1085US11267883B2Antibodies that specifically bind to human IL-15 and uses thereofCEPHALON INC·Filed 2017·Granted Mar 8, 2022·5 cites·27 claims
- 1184US2025179202A1Antibodies That Specifically Bind to TL1A and Methods of Treating Skin DiseaseCEPHALON LLC·Filed 2024·Application pending·0 cites
- 1283US12410256B2Antibodies that specifically bind to TL1a and methods of treating gastrointestinal or lung diseasesTEVA PHARMACEUTICALS AUSTRALIA PTY LTD·Filed 2023·Granted Sep 9, 2025·0 cites·19 claims
- 1383US11319356B2Interferon alpha 2B variantsTEVA PHARMACEUTICALS AUSTRALIA PTY LTD·Filed 2019·Granted May 3, 2022·2 cites·18 claims
- 1483US10981986B2Fusions of antibodies to CD38 and attenuated interferon alphaTEVA PHARMACEUTICALS AUSTRALIA PTY LTD·Filed 2017·Granted Apr 20, 2021·2 cites·21 claims
- 1582US10906973B2Antibody variants transmigrating the blood-brain barrier and uses thereofNAT RES COUNCIL CANADA·Filed 2017·Granted Feb 2, 2021·3 cites·19 claims
- 1678US2024301076A1Anti-cxcr2 antibodies and uses thereofCEPHALON LLC·Filed 2024·Application pending·0 cites
- 1777US12384841B2Anti-PAR-2 antibodies and methods of use thereofCEPHALON LLC·Filed 2023·Granted Aug 12, 2025·0 cites·3 claims
- 1877US12162946B2Antibodies that specifically bind to TL1A and methods of treating gastrointestinal diseaseCEPHALON LLC·Filed 2021·Granted Dec 10, 2024·0 cites·31 claims
- 1975US11332534B2Anti-CXCR2 antibodies and uses thereofCEPHALON INC·Filed 2019·Granted May 17, 2022·1 cites·13 claims
- 2075US11117975B2Anti-CD38 antibodies and fusions to attenuated interferon alpha-2BTEVA PHARMACEUTICALS AUSTRALIA PTY LTD·Filed 2018·Granted Sep 14, 2021·1 cites·13 claims
- 2173US12018084B2Anti-CXCR2 antibodies and uses thereofCEPHALON LLC·Filed 2022·Granted Jun 25, 2024·0 cites·25 claims
- 2271US12410247B2Polynucleotides encoding antibodies that specifically bind to human IL-15CEPHALON LLC·Filed 2022·Granted Sep 9, 2025·0 cites·20 claims
- 2369US9127057B2Anti-IL-23 heterodimer specific antibodiesCLARKE ADAM WILLIAM·Filed 2011·Granted Sep 8, 2015·2 cites·16 claims
- 2469US8470320B2Humanised antibodies with anti-tumour activityCLARKE ADAM W·Filed 2010·Granted Jun 25, 2013·2 cites·50 claims
- 2569US2022220184A1Interferon alpha 2b variantsTEVA PHARMACEUTICALS AUSTRALIA PTY LTD·Filed 2022·Application pending·0 cites
- 2668US2021347904A1Antibodies against tl1a and uses thereofTEVA PHARMACEUTICALS AUSTRALIA PTY LTD·Filed 2020·Application pending·0 cites
- 2764US2014255302A1ANTIBODIES AGAINST TL1a AND USES THEREOFTEVA PHARMACEUTICALS AUSTRALIA PTY LTD·Filed 2014·Application pending·0 cites
- 2854US8901279B2Humanized antibodies with anti-tumor activityTEVA PHARMACEUTICALS AUSTRALIA PTY LTD·Filed 2013·Granted Dec 2, 2014·0 cites·27 claims
- 2954US2016367695A1Polypeptide constructs and uses thereofTEVA PHARMACEUTICALS AUSTRALIA PTY LTD·Filed 2016·Application pending·0 cites
- 3043US2020110776A1Metamodel for graph databaseATC IP LLC·Filed 2019·Application pending·0 cites
- 3142US2014286957A1ANTIBODIES TO CD1dTEVA PHARMACEUTICALS AUSTRALIA PTY LTD·Filed 2014·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Matthew Pollard files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →